A Phase Ia/b study of MEK1/2 inhibitor PD-0325901 or MEK-162 with cMET inhibitor PF-02341066 in RASMT and RASWT (with aberrant c-MET) Colorectal Cancer Patients.

Project Information

MERCURIC

Grant agreement ID: 602901

Project closed

Start date 1 December 2013

End date 31 December 2019

Funded under

• Specific Programme "Cooperation": Health

Total cost

€ 4 552 218,68

EU contribution

€ 3 458 520,48

Coordinated by

THE QUEEN'S UNIVERSITY OF BELFAST
United Kingdom

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .